ODI Pharma AB hereby announced that the Company has secured loan financing of EUR 350,000 from an external international party in order to create flexibility in the operations. ODI has, as communicated in January 2023, received approval of the Company's Marketing Authorization Holder (MAH) application from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market. The Company thus has the right to distribute and sell its medical cannabis products on the Polish market.

Simultaneously, ODI has continued the work on establishing the skincare brand kandol. and ensuring that it can be offered to the market through ODI's collaborations with European retailers, skin clinics, pharmaceutical distribution platforms and online partners. In order to create further financial flexibility in the operations, the Company has secured a loan financing of EUR 350,000 from PSE Topsource SL.

The loan runs with an interest rate of 1.7% per started 30-day period during until the maturity date, which is on February 29th, 2024. ODI can repay the loan and interest at any time before the maturity date. Apart from this loan, ODI has no short- or long-term interest-bearing liabilities.